GUD vs. TLRY, CRON, THCX, WEED, ACB, FIRE, CRDL, OGI, EPI, and ICC
Should you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Tilray Brands (TLRY), Cronos Group (CRON), Hydropothecary (THCX), Canopy Growth (WEED), Aurora Cannabis (ACB), Supreme Cannabis (FIRE), Cardiol Therapeutics (CRDL), Organigram (OGI), ESSA Pharma (EPI), and ICC Labs (ICC). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Tilray Brands (TSE:TLRY) and Knight Therapeutics (TSE:GUD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation.
In the previous week, Knight Therapeutics had 2 more articles in the media than Tilray Brands. MarketBeat recorded 2 mentions for Knight Therapeutics and 0 mentions for Tilray Brands. Knight Therapeutics' average media sentiment score of 0.00 beat Tilray Brands' score of -0.16 indicating that Tilray Brands is being referred to more favorably in the media.
Knight Therapeutics has a net margin of -5.25% compared to Knight Therapeutics' net margin of -47.35%. Tilray Brands' return on equity of -2.21% beat Knight Therapeutics' return on equity.
Knight Therapeutics received 110 more outperform votes than Tilray Brands when rated by MarketBeat users. Likewise, 74.32% of users gave Knight Therapeutics an outperform vote while only 0.00% of users gave Tilray Brands an outperform vote.
Knight Therapeutics has lower revenue, but higher earnings than Tilray Brands. Knight Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.
Tilray Brands currently has a consensus price target of C$2.95, suggesting a potential upside of 20.41%. Knight Therapeutics has a consensus price target of C$6.75, suggesting a potential upside of 12.50%. Given Knight Therapeutics' higher possible upside, research analysts clearly believe Tilray Brands is more favorable than Knight Therapeutics.
12.2% of Tilray Brands shares are held by institutional investors. Comparatively, 13.7% of Knight Therapeutics shares are held by institutional investors. 1.2% of Tilray Brands shares are held by company insiders. Comparatively, 46.4% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Tilray Brands has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. Comparatively, Knight Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.
Summary
Knight Therapeutics beats Tilray Brands on 11 of the 17 factors compared between the two stocks.
Get Knight Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Knight Therapeutics Competitors List
Related Companies and Tools
